O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+15.41%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.46B
AUM Growth
+$5.46B
(+8.6%)
Cap. Flow
-$50.4M
Cap. Flow
% of AUM
-0.92%
Top 10 Holdings %
Top 10 Hldgs %
41.94%
Holding
129
New
17
Increased
19
Reduced
31
Closed
16
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$99M |
| 2 |
UnitedHealth
UNH
|
$39.2M |
| 3 |
Sarepta Therapeutics
SRPT
|
$38.5M |
| 4 |
Amgen
AMGN
|
$37.8M |
| 5 |
Universal Health Services
UHS
|
$35.7M |
Top Sells
| 1 |
Janux Therapeutics
JANX
|
$78.2M |
| 2 |
Tenet Healthcare
THC
|
$65M |
| 3 |
Vaxcyte
PCVX
|
$46.7M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$41.4M |
| 5 |
Geron
GERN
|
$37.9M |
Sector Composition
| 1 | Healthcare | 99.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Terns Pharmaceuticals
TERN
$651M
| $63.1M | 1.15% |
7,562,971
-56,164
| -0.7% | -$468K |
|
27
Keros Therapeutics
KROS
$640M
| $59.2M | 1.07% |
1,018,734
-250,000
| -20% | -$14.5M |
|
|
28
Janux Therapeutics
JANX
$1.38B
| $57.2M | 1.04% |
1,258,566
-1,721,262
| -58% | -$78.2M |
|
29
Elevance Health
ELV
$72.4B
| $55.2M | 1% |
106,200
-61,900
| -37% | -$32.2M |
|
30
Crinetics Pharmaceuticals
CRNX
$3.26B
| $53.7M | 0.98% |
1,050,055
-230,745
| -18% | -$11.8M |
|
31
Thermo Fisher Scientific
TMO
$183B
| $52.2M | 0.95% |
84,400
-47,600
| -36% | -$29.4M |
|
32
Xtant Medical Holdings
XTNT
$82.4M
| $49.4M | 0.9% |
73,114,592
| – | – |
|
33
Avidity Biosciences
RNA
$6.12B
| $48M | 0.87% |
1,044,805
+338,330
| +48% | +$15.5M |
|
34
Regeneron Pharmaceuticals
REGN
$59.8B
| $47.5M | 0.86% |
45,200
+22,400
| +98% | +$23.5M |
|
35
Evolent Health
EVH
$1.11B
| $47.1M | 0.86% |
1,665,115
-940,500
| -36% | -$26.6M |
|
36
Exact Sciences
EXAS
$9.33B
| $46.3M | 0.84% |
679,816
+7,400
| +1% | +$504K |
|
37
SI-BONE Inc
SIBN
$700M
| $46.2M | 0.84% |
3,305,801
+75,824
| +2% | +$1.06M |
|
|
SWTX
38
DELISTED
SpringWorks Therapeutics
SWTX
| $44.6M | 0.81% |
1,390,631
-316,700
| -19% | -$10.1M |
|
|
39
Vaxcyte
PCVX
$4.17B
| $44.2M | 0.8% |
387,000
-408,900
| -51% | -$46.7M |
|
40
Compass Therapeutics
CMPX
$466M
| $41.1M | 0.75% |
22,362,850
| – | – |
|
41
Cytokinetics
CYTK
$5.98B
| $40.5M | 0.74% |
766,906
-46,000
| -6% | -$2.43M |
|
42
Syndax Pharmaceuticals
SNDX
$1.39B
| $37.1M | 0.67% |
1,925,300
| – | – |
|
43
Corvus Pharmaceuticals
CRVS
$419M
| $36.7M | 0.67% |
6,943,654
| – | – |
|
44
Apellis Pharmaceuticals
APLS
$3.51B
| $36.6M | 0.67% |
1,270,400
-32,400
| -2% | -$934K |
|
45
Xenon Pharmaceuticals
XENE
$2.99B
| $35.9M | 0.65% |
911,420
+49,058
| +6% | +$1.93M |
|
|
46
Universal Health Services
UHS
$11.6B
| $35.7M | 0.65% |
+156,000
| New | +$35.7M |
|
47
Icon
ICLR
$14B
| $35.6M | 0.65% |
123,900
-50,200
| -29% | -$14.4M |
|
48
Neurocrine Biosciences
NBIX
$13.5B
| $34.8M | 0.63% |
302,220
-145,980
| -33% | -$16.8M |
|
49
Vera Therapeutics
VERA
$1.47B
| $29.9M | 0.54% |
675,872
| – | – |
|
|
BIOA
50
BioAge Labs, Inc. Common Stock
BIOA
$170M
| $29.6M | 0.54% |
+1,423,470
| New | +$29.6M |
|